Clinical trials: Non-valvular Atrial Fibrillation (NVAF)
Atrial Fibrillation
Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
To describe the rate of discontinuation among Non-Valvular Atrial Fibrillation (NVAF) patients who were on warfarin and have switched to the Novel oral anticoagulants(NOACs).
- Trial name
- NCT02792335
- Testing
- apixaban, dabigatran, rivaroxaban
- Volunteers
- 28,000 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Real-world Comparative Effectiveness of Rivaroxaban Versus VKA
To obtain a better understanding on the comparative effectiveness of rivaroxaban versus VKA(Vitamin K antagonist) for stroke prevention in patients with NVAF(non-valvular atrial fibrillation) in a real-life setting
- Trial name
- RIVA-F (NCT02690155)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), VKA (Vitamin K antagonist)
- Where
- United States
- Volunteers
- 38,831 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (NVAF)
Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan
The objective of this study is to understand if Rivaroxaban can improve treatment satisfaction of Warfarin patients and assess the safety and effectiveness of Xarelto in real clinical practice.
- Trial name
- NCT01598051
- Testing
- Rivaroxaban (Xarelto_ BAY59-7939)
- Where
- Japan
- Volunteers
- 741 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation
Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment
While it is well known that stopping or changing medication with blood thinners in patients who suffer from non-valvular atrial fibrillation (NVAF) increases the risk of ischemic stroke (a condition which occurs when a vessel…
- Trial name
- RITMUS-AF (NCT04174859)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Italy
- Volunteers
- 812 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (NVAF), Thromboembolism
Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)
This is a multi-center, prospective, open-label, randomized controlled trial (STEP-AF) designed to evaluate the safety of a stepwise anticoagulation strategy compared with the guideline-recommended standard anticoagulation…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Thromboembolism, Cardiac Implantable Electronic Device, Perioperative Bleeding
- Trial name
- STEP-AF (NCT07616414)
- Testing
- Stepwise Anticoagulation Regimen, Standard Anticoagulation Regimen
- Where
- China
- Volunteers
- 424 people
- Sponsor
- Fu Wai Hospital, Beijing, China
Atrial Fibrillation
A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and Diabetes
In people with type 2 diabetes, the body does not make enough of a hormone called insulin or does not use insulin well. This results in high blood sugar levels.
- Trial name
- RIVA-DM (NCT04509193)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Warfarin
- Where
- United States
- Volunteers
- 116,049 people
- Sponsor
- Bayer
Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE)
Precision Antithrombotic Therapy
The goal of this observational study is to systematically analyze the relationship between trough/peak concentrations of novel oral anticoagulants (NOACs) and antiplatelet drugs with clinical events, aiming to provide high-level…
- Conditions
- Non-valvular Atrial Fibrillation (NVAF), Venous Thromboembolism (VTE), MI(Myocardial Infarction), Ischemic Stroke
- Trial name
- NCT07654634
- Testing
- Not applicable- observational study
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Atrial Fibrillation, Percutaneous Coronary Intervention
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
The main objective of this study is to compare a Dual Antithrombotic Therapy (DAT) regimen of 110mg dabigatran etexilate b.i.d. plus clopidogrel or ticagrelor (110mg dabigatran etexilate (DE) DAT) and 150mg dabigatran etexilate…
- Trial name
- NCT02164864
- Testing
- Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin
- Where
- 421 sites in United States, Argentina and 39 more
- Volunteers
- 2,725 people
- Sponsor
- Boehringer Ingelheim
Non-valvular Atrial Fibrillation (NVAF)
A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)
This study is planned to collect prospective data and evaluate the safety and effectiveness of rivaroxaban for the prevention of stroke and systemic embolism in Indian patients with NVAF when used in clinical practice under…
- Trial name
- XARIN (NCT03887780)
- Testing
- Rivaroxaban (Xarelto,Bay 59-7939)
- Where
- India
- Volunteers
- 504 people
- Sponsor
- Bayer
Atrial Fibrillation
Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan
The primary objective of this study is to compare the Length of Stay from treatment of oral anticoagulant initiation to hospital discharge of patients hospitalized and subsequently treated with dabigatran or warfarin for…
- Trial name
- NCT02631057
- Testing
- Dabigatran, Warfarin
- Where
- 2 sites in Japan
- Volunteers
- 4,313 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke, Atrial Fibrillation Symptomatic
Cerebral Microbleeds During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW)
Anticoagulants are generally recognized as a necessary therapy to prevent the recurrence of ischemic stroke in patients with non-valvular atrial fibrillation (NVAF), but in some patients they also cause bleedings, particularly…
- Trial name
- CMB-NOW (NCT02356432)
- Where
- 3 sites in Japan
- Volunteers
- 86 people
- Sponsor
- Tokai University
Atrial Fibrillation
Safety and Effectiveness of Low Dose Edoxaban in Patients With NVAF
The efficacy and safety of edoxaban has not been adequately studied in Asians versus non-Asians, who are quite different physiologically from each other.
- Trial name
- LEDIOS (NCT03554837)
- Where
- South Korea
- Volunteers
- 2,562 people
- Sponsor
- Samsung Medical Center
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
An anticoagulation therapy is a critical treatment to prevent thromboembolism in non-valvular AF (NVAF) patients. Warfarin, a vitamin K antagonist, is the first oral anticoagulant approved for the treatment for prevention of…
- Trial name
- CER3 (NCT03570047)
- Where
- Japan
- Volunteers
- 73,989 people
- Sponsor
- Pfizer
Non-valvular Atrial Fibrillation (NVAF)
Early Post-marketing Study of Eliquis (Apixaban)
The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.
- Trial name
- NCT02153424
- Testing
- Apixaban
- Where
- 2 sites in Mexico
- Sponsor
- Bristol-Myers Squibb
Non-valvular Atrial Fibrillation (NVAF)
To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adult Volunteers
To compare the pharmacokinetics and safety after a single dose administration of IN-G00002 and IN-R00002 in healthy adult volunteers
- Trial name
- NCT06725355
- Testing
- IN-R00002, IN-G00002
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Intracranial Hemorrhages, Atrial Fibrillation (AF)
Comparison of LAA-Closure vs Oral Anticoagulation in Patients With NVAF and Status Post Intracranial Bleeding.
Atrial fibrillation is the most common cardiac arrhythmia. In atrial fibrillation, there is a risk that clots can form in the heart, especially in the left atrium. If these clots come loose, there is a risk of stroke.
- Conditions
- Intracranial Hemorrhages, Atrial Fibrillation (AF), Atrial Flutter
- Trial name
- CLEARANCE (NCT04298723)
- Testing
- Percutaneous closure of the LAA (Watchman / Watchman FLX)
- Where
- 39 sites in Germany, Poland
- Volunteers
- 530 people
- Sponsor
- Jena University Hospital
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
The purpose of this study are 1) to characterize the primary and secondary prevention patients, 2) to calculate incidence rates of stroke/SE or major bleeding in each cohort and 3) to investigate for Japanese secondary prevention…
- Trial name
- NCT05321810
- Testing
- Apixaban, Warfarin
- Where
- Japan
- Volunteers
- 193,565 people
- Sponsor
- Pfizer
Non-valvular Atrial Fibrillation (NVAF), Chronic Kidney Disease (CKD)
Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry
The multicenter registry will collect clinical data from 1600 patients with non valvular atrial fibrillation (NVAF) and chronic kidney disease (eGFR 15-49 mL/min per 1.73 m2).
- Trial name
- XARENO (NCT02663076)
- Where
- 121 sites in Austria, Belgium and 3 more
- Volunteers
- 1,700 people
- Sponsor
- GWT-TUD GmbH
Stroke
Use of Direct Oral Anticoagulants in UK
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it.
- Trial name
- NCT03119116
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Dabigatran, Apixaban
- Where
- United Kingdom
- Volunteers
- 31,336 people
- Sponsor
- Bayer
Acute Coronary Syndrome (ACS), Non-valvular Atrial Fibrillation (NVAF)
Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)
It is a multi-center randomized clinical trial (RCT) which will enroll 3746 patients with acute coronary syndrome (ACS) concomitant non-valvular atrial fibrillation (NVAF) and undergoing new generation drug eluting stent (DES)…
- Trial name
- NCT03234114
- Testing
- Triple antithrombotic therapy, Dual antithrombotc therapy-1, Dual antithrombotc therapy-2
- Where
- China
- Volunteers
- 3,746 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University